Athenex, Inc (ATNX)

Etorro trading 970x250
Athenex, Inc (ATNX) Logo

About Athenex, Inc

Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company’s Orascovery product candidates include Oral Paclitaxel, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignancies and gastric cancer; and Oral Irinotecan and Encequidar, a potent anticancer drug that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer. Its Orascovery product candidates also comprise Oral Docetaxel and Encequidar, a potent anticancer drug, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oral Topotecan and Encequidar, a potent anticancer drug that is Phase I clinical trial to treat lung, ovarian, and cervical cancer; and Oral Eribulin and Encequidar, an anticancer intravenous drug to treat certain patients with breast cancer and liposarcoma. In addition, the company offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis; Tirbanibulin Oral for solid and liquid tumors; and KX2-361 for glioblastoma multiforme. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome P450 enzymes within the gastrointestinal tract; T Cell Receptor Engineered T Cell, a cell-based immunotherapy; and PT01 (Pegtomarginase), an arginine deprivation therapy product. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was incorporated in 2003 and is headquartered in Buffalo, New York. Address: Conventus Building, Buffalo, NY, United States, 14203

Athenex, Inc News and around…

Latest news about Athenex, Inc (ATNX) common stock and company :

Inside the Athenex-ImmunityBio deal — and the California company's employment plans
13 Jan, 2022 Yahoo! Finance

A relationship that began at American Pharmaceutical Partners, which had a longtime plant on Grand Island, led the immunotherapy and cell therapy company to Dunkirk.

12 Health Care Stocks Moving In Thursday's Pre-Market Session
13 Jan, 2022 FinancialContent

Gainers iSpecimen (NASDAQ:ISPC) shares rose 19.8% to $8.18 during Thursday's pre-market session. The market value of ...

ImmunityBio Expands Manufacturing Capacity with State-of-the-Art Manufacturing Plant in New York for Global Pandemic Response and Preparedness
12 Jan, 2022 FinancialContent

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company (“ImmunityBio”), today announced that it has entered into a definitive agreement to acquire a leasehold interest in 409,000 square feet of ISO Class 5 pharmaceutical manufacturing space in western New York (the “Dunkirk Facility”), and certain related assets, from global pharmaceutical company Athenex, Inc. (NASDAQ: ATNX) (“Athenex”). The agreement will provide ImmunityBio with a state-of-the-art biotech production facility that will substantially expand and diversify ImmunityBio’s existing manufacturing capacity in the U.S., South Africa, and Botswana through its strategic collaborators.

Athenex Announces Agreement with ImmunityBio Regarding Dunkirk Manufacturing Facility
12 Jan, 2022 Yahoo! Finance

BUFFALO, N.Y., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that it has entered into a definitive agreement for ImmunityBio, Inc. (NASDAQ: IBRX) to assume its leasehold interest in a manufacturing facility in Dunkirk, New York, and certain related assets for approximately $38 million, subject t

Stocks That Hit 52-Week Lows On Friday
07 Jan, 2022 FinancialContent

Before 10 am on Friday, 110 companies set new 52-week lows. Interesting Points From Today's 52-Week Lows: Humana ...

SHAREHOLDER ALERT: Robbins LLP is Investigating Athenex, Inc. (ATNX) for Shareholders
29 Dec, 2021 FinancialContent

Athenex, Inc. (ATNX) Misstated the Efficacy of its Lead Drug Candidate and the Likelihood the FDA Would Approve its New Drug Application

Are Options Traders Betting on a Big Move in Athenex (ATNX) Stock?
20 Dec, 2021 Yahoo! Finance

Investors need to pay close attention to Athenex (ATNX) stock based on the movements in the options market lately.

Athenex to Host a KOL Webinar Today on CAR-NKT Cell Approach to Cancer and Latest Data at the 63rd ASH Annual Meeting
13 Dec, 2021 Yahoo! Finance

The Company will host a virtual Key Opinion Leader event today at 9:00 a.m. ET to discuss its CAR-NKT cell therapy platform Interim results from five evaluable patients in ANCHOR study of KUR-502 showed 80% Overall Response Rate and 60% Complete Response at lowest dose levels BUFFALO, N.Y., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cance

Athenex to Host Key Opinion Leader Webinar on CAR-NKT Approach to Cancer
30 Nov, 2021 Yahoo! Finance

Presentations Will Include a Review of ANCHOR Study Data on KUR-502 from ASH Annual Meeting Webinar on Monday, December 13th, at 9:00 a.m. ET BUFFALO, N.Y., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it will host a virtual key opinion leader (KOL) event on its CAR-NKT technology on Monda

Athenex Announces UK MHRA Validation of the Marketing Authorization Application for Oral Paclitaxel and Encequidar for Review
29 Nov, 2021 Yahoo! Finance

BUFFALO, N.Y., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that its Marketing Authorization Application (MAA) for oral paclitaxel and encequidar (Oral Paclitaxel) for the treatment of advanced breast cancer has been validated by the United Kingdom’s (UK) Medicines and Healthcare products Regul

Athenex To Present Subgroup Analysis Of Oral Paclitaxel-Encequidar Combo Data From Breast Cancer Trial
22 Nov, 2021 FinancialContent

Athenex Inc's(NASDAQ: ATNX) abstract for subgroup analysis of its Phase 3 study of oral paclitaxel and encequidar (Oral ...

Athenex to Present Subgroup Analysis from Phase 3 Study of Oral Paclitaxel Plus Encequidar (KX-ORAX-001) in Metastatic Breast Cancer at SABCS 2021
22 Nov, 2021 Yahoo! Finance

Analysis of safety data demonstrated that patients with elevated liver tests were at increased risk of neutropenia related toxicities Post hoc analysis of this subgroup of patients with hepatic impairment was conducted and showed a median survival rate of 18.9 months in patients treated with Oral Paclitaxel vs 10.1 months in those treated with IV Paclitaxel, with a hazard ratio of 0.59 This increase in overall survival counterbalanced the risk of complications of neutropenia related toxicities B

Interesting ATNX Call Options For July 2022
19 Nov, 2021 FinancialContent

Investors in Athenex Inc (ATNX) saw new options become available this week, for the July 2022 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 238 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

Athenex to Present at the Evercore ISI 4th Annual HealthCONx Conference
18 Nov, 2021 Yahoo! Finance

BUFFALO, N.Y., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that Johnson Lau, CEO and Board Chairman, and Daniel Lang, Senior Director, Corporate Development will present at the Evercore ISI 4th Annual HealthCONx Conference on Tuesday, November 30, 2021 at 3:55 pm ET. A live audio webcast of th

4 Penny Stocks Insiders Are Buying
15 Nov, 2021 FinancialContent

When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors ...

Implied BIB Analyst Target Price: $113
11 Nov, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the ProShares ProShares Ultra Nasdaq Biotechnology ETF (BIB), we found that the implied analyst target price for the ETF based upon its underlying holdings is $113.07 per unit.

Athenex Announces Exclusive License Agreement with National Cancer Institute to Utilize T Cell Receptors Targeting Mutated p53, KRAS, and EGFR for the Development of Autologous and Allogeneic Cell Therapies
09 Nov, 2021 Yahoo! Finance

Athenex plans to expand the allogeneic NKT cell R&D pipeline with these new licensed TCRs to target solid tumorsBUFFALO, N.Y., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced a licensing agreement with the National Cancer Institute (NCI), an institute of the National Institutes of Health (NIH), to expand

Athenex, inc (ATNX) Q3 2021 Earnings Call Transcript
07 Nov, 2021 FinancialContent

ATNX earnings call for the period ending September 30, 2021.

Athenex (ATNX) Reports Q3 Loss, Tops Revenue Estimates
04 Nov, 2021 Yahoo! Finance

Athenex (ATNX) delivered earnings and revenue surprises of 19.51% and 66.48%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Athenex Presents Interim Data from ANCHOR Study of KUR-502 (Allogeneic CD19 CAR-NKT Cells) in Relapsed or Refractory Lymphoma and Leukemia at 63rd ASH Annual Meeting and Exposition
04 Nov, 2021 Yahoo! Finance

Results from five patients showed best responses of 2 partial responses (PR), 1 complete response with incomplete hematological recovery (CRi) and 1 complete response (CR). Updated data show continued favorable safety profile and encouraging anti-tumor activity in adult patients treated with low doses of KUR-502. Study continues to accrue to higher doses. BUFFALO, N.Y., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery,

Athenex Provides Third Quarter 2021 Corporate and Financial Update
04 Nov, 2021 Yahoo! Finance

Held FDA Type A Meeting for oral paclitaxel in metastatic breast cancer Klisyri® launched in Europe ANCHOR Phase 1 interim results accepted for poster presentation at 2021 ASH 3Q product sales were $27.0M, up 9% year-over-year Company now expects full year product sales revenue in 2021 to decrease by 6-12% compared to 2020 Management to host conference call and webcast today at 10:00 a.m. ET BUFFALO, N.Y., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutica

Earnings Preview For Athenex
03 Nov, 2021 FinancialContent

Athenex (NASDAQ:ATNX) is set to give its latest quarterly earnings report on Thursday, 2021-11-04. Here's what investors need to know ...

Athenex (ATNX) Sees Hammer Chart Pattern: Time to Buy?
03 Nov, 2021 Yahoo! Finance

Athenex (ATNX) has been struggling lately, but the selling pressure may be coming to an end soon.

Investors in Athenex (NASDAQ:ATNX) have unfortunately lost 79% over the last three years
02 Nov, 2021 Yahoo! Finance

As every investor would know, not every swing hits the sweet spot. But you have a problem if you face massive losses...

Athenex to Provide Corporate and Financial Update for the Third Quarter 2021, on November 4, 2021
22 Oct, 2021 Yahoo! Finance

BUFFALO, N.Y., Oct. 22, 2021 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a corporate and financial update for the third quarter 2021, on Thursday, November 4, 2021. Athenex’s management team will host a conference call and live audio webcast at 10:00 a.m. Eastern Time. To participate

Athenex to Provide Corporate and Financial Update for the Third Quarter 2021, on November 5, 2021
21 Oct, 2021 Yahoo! Finance

BUFFALO, N.Y., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a corporate and financial update for the third quarter 2021, on Friday, November 5, 2021, before the market opens. Athenex’s management team will host a conference call and live audio webcast at 8:00am Eastern Ti

Athenex and the Center for Cell and Gene Therapy Announce Allowance of Our First U.S. Patent Claims Around CAR-NKT Cell Therapy
18 Oct, 2021 Yahoo! Finance

Patent includes a pharmaceutical composition claim comprising a plurality of genetically modified CD62L-positive human NKT cells comprising at least one chimeric antigen receptor (CAR) Patent protection helps validate the groundbreaking innovation of Dr. Leonid Metelitsa in harnessing NKT cell technologies for adoptive cell transfer therapy in oncology BUFFALO, N.Y., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), the leading developer of NKT cell therapy and the Center for Cell and Ge

Interesting ATNX Put And Call Options For December 17th
15 Oct, 2021 FinancialContent

Investors in Athenex Inc (ATNX) saw new options become available this week, for the December 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ATNX options chain for the new December 17th contracts and identified one put and one call contract of particular interest.

Thursday 10/14 Insider Buying Report: SLGG, ATNX
14 Oct, 2021 FinancialContent

As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys.

3 Penny Stocks Insiders Are Buying
14 Oct, 2021 FinancialContent

When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and ...

Athenex, Inc (ATNX) is a NASDAQ Common Stock listed in , ,

970x250